The incremental healthcare cost associated with cancer in Belgium: A registry-based data analysis.
burden of disease
cancer
cost-of-illness
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
revised:
04
09
2023
received:
26
05
2023
accepted:
03
10
2023
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
25
1
2024
Statut:
aheadofprint
Résumé
Similar to many countries, Belgium experienced a rapid increase in cancer diagnoses in the last years. Considering that a large part of cancer types could be prevented, our study aimed to estimate the annual healthcare burden of cancer per site, and to compare cost with burden of disease estimates to have a better understanding of the impact of different cancer sites in Belgium. We used nationally available data sources to estimate the healthcare expenditure. We opted for a prevalence-based approach which measures the disease attributable costs that occur concurrently for 10-year prevalent cancer cases in 2018. Average attributable costs of cancer were computed via matching of cases (patients with cancer by site) and controls (patients without cancer). Years of life lost due to disability (YLD) were used to summarize the health impact of the selected cancers. The highest attributable cost in 2018 among the selected cancers was on average €15,867 per patient for bronchus and lung cancer, followed by liver cancer, pancreatic cancer, and mesothelioma. For the total cost, lung cancer was the most costly cancer site with almost €700 million spent in 2018. Lung cancer was followed by breast and colorectal cancer that costed more than €300 million each in 2018. In our study, the direct attributable cost of the most prevalent cancer sites in Belgium was estimated to provide useful guidance for cost containment policies. Many of these cancers could be prevented by tackling risk factors such as smoking, obesity, and environmental stressors.
Sections du résumé
BACKGROUND
BACKGROUND
Similar to many countries, Belgium experienced a rapid increase in cancer diagnoses in the last years. Considering that a large part of cancer types could be prevented, our study aimed to estimate the annual healthcare burden of cancer per site, and to compare cost with burden of disease estimates to have a better understanding of the impact of different cancer sites in Belgium.
METHODS
METHODS
We used nationally available data sources to estimate the healthcare expenditure. We opted for a prevalence-based approach which measures the disease attributable costs that occur concurrently for 10-year prevalent cancer cases in 2018. Average attributable costs of cancer were computed via matching of cases (patients with cancer by site) and controls (patients without cancer). Years of life lost due to disability (YLD) were used to summarize the health impact of the selected cancers.
RESULTS
RESULTS
The highest attributable cost in 2018 among the selected cancers was on average €15,867 per patient for bronchus and lung cancer, followed by liver cancer, pancreatic cancer, and mesothelioma. For the total cost, lung cancer was the most costly cancer site with almost €700 million spent in 2018. Lung cancer was followed by breast and colorectal cancer that costed more than €300 million each in 2018.
CONCLUSIONS
CONCLUSIONS
In our study, the direct attributable cost of the most prevalent cancer sites in Belgium was estimated to provide useful guidance for cost containment policies. Many of these cancers could be prevented by tackling risk factors such as smoking, obesity, and environmental stressors.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Gorasso V, Silversmit G, Arbyn M, et al. The non-fatal burden of cancer in Belgium, 2004-2019: a nationwide registry-based study. BMC Cancer. 2022;22(1):58. doi:10.1186/s12885-021-09109-4
Schlueter M, Chan K, Lasry R, Price M. The cost of cancer-a comparative analysis of the direct medical costs of cancer and other major chronic diseases in Europe. PloS One. 2020;15(11):e0241354. doi:10.1371/journal.pone.0241354
Hofmarcher T, Lindgren P, Wilking N, Jönsson B. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41-49. doi:10.1016/j.ejca.2020.01.011
Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy. 2006;77(1):51-63. doi:10.1016/j.healthpol.2005.07.016
Wilking NE, Hofmarcher T, Lindgren P, Jönsson B. The burden and direct cost of cancer in Europe (EU-28). J Clin Oncol. 2016;34(15):6618. doi:10.1200/JCO.2016.34.15_suppl.6618
Pil L, Hoorens I, Vossaert K, Brochez L, Annemans L. The Impact of Skin Cancer in Belgium and the Cost-Effectiveness of Prevention. KCE; 2016.
Broekx S, Hond ED, Torfs R, et al. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ. 2011;12(4):311-317. doi:10.1007/s10198-010-0237-3
Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653-671. doi:10.2165/11588380-000000000-00000
Belgian Cancer Registry. Cancer Burden in Belgium 2004-2017. 2020 [Online]. https://kankerregister.org/media/docs/CancerBurdenfeb2020reduced.pdf
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2021. https://www.R-project.org/
Keiding N, Clayton D. Standardization and control for confounding in observational studies: a historical perspective. Stat Sci. 2014;29(4). doi:10.1214/13-STS453
Snowden JM, Rose S, Mortimer KM. Implementation of G-computation on a simulated data set: demonstration of a causal inference technique. Am J Epidemiol. 2011;173(7):731-738. doi:10.1093/aje/kwq472
Henderson RH, French D, Maughan T, et al. The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. Lancet Gastroenterol Hepatol. 2021;6(9):709-722. doi:10.1016/S2468-1253(21)00147-3
Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomark Prev. 2020;29(7):1304-1312. doi:10.1158/1055-9965.EPI-19-1534
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327-337. doi:10.3350/cmh.2014.20.4.327
Hernán MA. Counterpoint: epidemiology to guide decision-making: moving away from practice-free research. Am J Epidemiol. 2015;182(10):834-839. doi:10.1093/aje/kwv215
Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175(4):250-262. doi:10.1093/aje/kwr301